Bruxism is characterized by grinding or clenching of the teeth, which results in characteristic grinding sounds, abnormal tooth wear and jaw and muscle pain. It can be classified as primary/idiopathic or secondary/ iatrogenic bruxism, which is associated with medication or medical diseases. Atomoxetine is the first non-stimulant medication for the treatment of Attention deficit hyperactivity disorder. It is a generally safe and well-tolerated drug. Most common adverse reactions include nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence. We report a case of dose-dependent bruxism induced by atomoxetine, which was observed in a child with Attention deficit hyperactivity disorder and adjustment disorder with anxiety. Atomoxetine treatment has been started at a dose of 18 mg/day and then increased up to 60 mg/day. A month later, the frequency and severity of these complaints were increased. Nevertheless, atomoxetine dose was tapered down to 40 mg/day and was continued in this way. At the meeting held a month after the disappearance of bruxism, there was no decline in improvement of ADHD symptoms.